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Objectives: Nisin is a lantibiotic widely used for the preservation of food and beverages.
Recently, investigators have reported that nisin may have clinical applications for treating
bacterial infections. The aim of this study was to investigate the effects of ultra pure food
grade Nisin ZP (>95% purity) on taxonomically diverse bacteria common to the human
oral cavity and saliva derived multi-species oral biofilms, and to discern the toxicity of
nisin against human cells relevant to the oral cavity.
Methods: The minimum inhibitory concentrations and minimum bactericidal
concentrations of taxonomically distinct oral bacteria were determined using agar and
broth dilution methods. To assess the effects of nisin on biofilms, two model systems
were utilized: a static and a controlled flow microfluidic system. Biofilms were inoculated
with pooled human saliva and fed filter-sterilized saliva for 20–22 h at 37◦C. Nisin effects
on cellular apoptosis and proliferation were evaluated using acridine orange/ethidium
bromide fluorescent nuclear staining and lactate dehydrogenase activity assays.
Results: Nisin inhibited planktonic growth of oral bacteria at low concentrations
(2.5–50 μg/ml). Nisin also retarded development of multi-species biofilms at
concentrations ≥1 μg/ml. Specifically, under biofilm model conditions, nisin interfered
with biofilm development and reduced biofilm biomass and thickness in a dose-
dependent manner. The treatment of pre-formed biofilms with nisin resulted in dose-
and time-dependent disruption of the biofilm architecture along with decreased bacterial
viability. Human cells relevant to the oral cavity were unaffected by the treatment of nisin
at anti-biofilm concentrations and showed no signs of apoptotic changes unless treated
with much higher concentrations (>200 μg/ml).
Conclusion: This work highlights the potential therapeutic value of high purity food
grade nisin to inhibit the growth of oral bacteria and the development of biofilms relevant
to oral diseases.
Keywords: nisin, dental plaque, saliva derived multi-species biofilms, human oral cells, confocal, apoptosis, oral
diseases
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Introduction
Dental plaque is an architecturally complex bacterial multi-
species bioﬁlm community (Marsh, 2010; Zijnge et al., 2010).
Hundreds of species can coexist in these communities and
together they can be up to 1000-times more resistant to
antimicrobials than their planktonic counterparts (Gilbert et al.,
2002; Aas et al., 2005). Enhanced antimicrobial resistance
accounts, in part, for the accumulation of pathogens that
are associated with dental caries, periodontal disease, and
pulpal infections (Marsh, 2003). Strategies to control bioﬁlms
and their contained species have met with diﬃculties, as is
evidenced by the public health burden associated with poor
oral health. The Centers for Disease Control and Prevention
(CDC) estimated that in the United States (US) alone, $108
billion was spent on dental services in 2010 and is therefore
constantly on the search for alternative cost-eﬀective preventative
strategies (Chronic Disease Prevention and Health Promotion,
2015). Given the public health burden associated with dental
plaque, new candidate anti-bioﬁlm technologies are currently
being investigated. These include modiﬁcations to traditional
approaches, such as the development of improved antimicrobial
compounds and formulations (zinc, cetylpyridinium chloride,
stannous compounds, natural agents) (Allaker and Douglas,
2009; Marsh, 2010) to more innovative technologies, such as
those that display antimicrobial but also anti-bioﬁlm eﬀects
(Kaplan, 2010). For example, there has been considerable interest
in approaches to inhibit cell–cell signaling between bacteria to
control oral bioﬁlm formation (Raﬀa et al., 2005; Barrios et al.,
2006; Rickard et al., 2006; Bordi and de Bentzmann, 2011;
Cuadra-Saenz et al., 2012) and to augment cell–cell signaling
for enhancing antimicrobial activity (Eckert et al., 2006; Ahmed
et al., 2009). In addition, there has been substantial interest
in approaches to structurally weaken bioﬁlms by targeting
bacterially produced extracellular polymeric substances (EPS)
using enzymes such as dispersin B (Izano et al., 2007). One
technology that has recently garnered attention is the use of
bacteriocins, such as nisin, which is produced by Lactococcus
lactis (Pepperney and Chikindas, 2011; Arthur et al., 2014).
Lactococcus lactis is a non-pathogenic, Gram-positive, lactic
acid bacterium used in food fermentation and found commonly
in dairy products (De Vuyst and Vandamme, 1994; Cleveland
et al., 2001). In addition, L. lactis has been proposed as a
probiotic agent (Vinderola and Reinheimer, 2003). Studies have
implied that lactic acid bacteria can prevent the co-localization of
pathogenic bacteria in certain microﬂora (intestinal, vaginal) by
stabilizing the complex bioﬁlm community (Todorov et al., 2007;
Kindrachuk et al., 2013). These processes may be mediated by
bacteriocins like nisin. Nisin is a bacterially secreted polypeptide
composed of 34-amino acids that exists as two natural variant
forms; nisin A and Z. The two variants diﬀer only by a single
amino acid at position 27; histidine in nisin A and asparagine in
nisin Z (Mulders et al., 1991). Nisin has amphipathic and cationic
properties, and is classiﬁed as a Type A (I) lantibiotic (Gross and
Morell, 1971; Asaduzzaman and Sonomoto, 2009). Lantibiotics
like nisin are known for their broad-spectrum Gram-positive
antimicrobial activities, high potency, low association with
cytotoxicity, and lack of stable and transmissible antimicrobial
resistance (Sahl and Bierbaum, 1998; Willey and van der Donk,
2007; Smith and Hillman, 2008). As a food preservative, nisin
has been granted GRAS (Generally Regarded as Safe) status by
the U.S. Food and Drug Administration (1988; FDA Federal
Register, 1998) for use in pasteurized, processed cheese spreads
and is currently licensed in 48 countries (Cotter et al., 2005).
Nisin acts by altering the structure of the cellular membrane
by forming short-lived pores and binding to the bacterial cell-
wall precursor lipid II with high aﬃnity (Breukink et al., 1999;
Wiedemann et al., 2001). This initial interaction facilitates further
modes of action to inhibit the cell wall biosynthesis, spore
outgrowth, and activation of autolytic enzymes (Peschel and
Sahl, 2006). Thus, the lack of bacterial resistance toward nisin
likely stems from its interaction with a number of distinct
targets.
Investigators from multiple ﬁelds have shown promising
results for the use of nisin to treat bacterial infections, such
as mastitis in humans and cows (Cao et al., 2007; Wu et al.,
2007; Fernández et al., 2008), Staphylococcus aureus infections in
atopic dermatitis (Valenta et al., 1996), respiratory tract infections
(Bush and Macielag, 2000; De Kwaadsteniet et al., 2009), and
experimental gingivitis in dogs (Howell et al., 1993). Recent
in vitro and in vivo evidence has even indicated a role for
nisin as an anticancer agent (Joo et al., 2012). Given the high
therapeutic potential of nisin, we hypothesize that nisin can be
utilized as an antimicrobial and anti-bioﬁlm agent to prevent
or treat oral bioﬁlm associated diseases. Thus, the aim of this
work was to determine the eﬀectiveness of nisin in inhibiting the
formation and maintenance of saliva derived multi-species oral
bioﬁlms. In addition, we examined the ability of nisin to inhibit
the growth of common oral bacteria found in the human oral
cavity, including both Gram-positive and Gram-negative, and
aerobic and anaerobic bacteria. Lastly, we examined the potential
cytotoxicity of nisin on human cells relevant to the oral cavity.
Materials and Methods
Nisin Preparation
An ultra pure food grade (>95%) form of the nisin Z, referred
to here as nisin ZP, was purchased from Handary (S.A., Brussels,
Belgium), a primary manufacturer of nisin in the food industry.
From here forward, nisin ZP will be referred to as nisin. Nisin
powder was stored at 4◦C in a vacuum desiccator (Thermo
Scientiﬁc, Waltham, MA, USA). The stock solution was prepared
at a concentration of 5 mg/ml in water, ﬁlter sterilized, and stored
at 4◦C for a maximum of 5 days for use in experiments.
Bacterial Strains and Growth Conditions
Streptococcus oralis 34 (kindly donated by P. E. Kolenbrander,
National Institutes of Health, Bethesda, MA, USA), Streptococcus
gordonii DL1 (kindly donated by P. E. Kolenbrander),
Streptococcus mutans UA159 (kindly donated by M. C. Peters,
University of Michigan, School of Dentistry, Ann Arbor, MI,
USA), Streptococcus mutans ATCC 25175, and Aggregatibacter
actinomycetemcomitans Y4 were grown on Brain Heart Infusion
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agar (BHI, Difco, Sparks, MD, USA) and cultured in BHI
broth media. Actinomyces odontolyticus ATCC 17982, Prevotella
intermedia (clinical isolate, kindly donated by W. Loesche,
University of Michigan, School of Dentistry, Ann Arbor, MI,
USA), Fusobacterium nucleatum ATCC 25586, were grown
on Fastidious Anaerobe Agar (Acumedia, Lansing, MI, USA)
containing 5% sheep blood and cultured in BHI broth media
supplemented with hemin (5 μg/ml) and Vitamin K (1 μg/ml).
Treponema denticola ATCC 35405 was grown in TYGVS broth
(Ohta et al., 1986; Fenno, 2005). All bacterial species mentioned
above were incubated at 37◦C under appropriate atmospheric
conditions in either an anaerobic chamber (Coy, Grass Lake, MI,
USA) or a 5% CO2 incubator. For each strain, a single colony was
inoculated into 5 ml of culture medium (as indicated above) and
incubated to exponential growth phase. For use in experiments,
the optical density at 600 nm (OD) of each culture was adjusted
approximately to 0.15 to correspond to a bacterial concentration
of 109 CFU/ml in culture medium.
MIC and MBC of Planktonic Oral Bacteria
The minimum inhibitory concentrations (MICs) and minimum
bactericidal concentrations (MBCs) of nisin against oral Gram-
positive and Gram-negative bacterial strains were determined
using the Clinical and Laboratory Standards Institute (CLSI)
standards with slight modiﬁcations as described below (Wikler,
2006; Wiegand et al., 2008). A total volume of 200 μl with
diﬀerent concentrations of nisin and the bacterial culture
suspended in BHI or TYGVS broth medium was added to a
96-well microplate (Costar, Corning Inc., NY, USA). Of the
total volume, each well contained 150 μl of bacterial culture
and 50 μl of nisin. As mentioned above, the initial optical
density of the bacterial cultures were calibrated approximately
to 0.15 (OD600) to achieve 109 CFU/ml. The ﬁnal working
concentrations of nisin were 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 15, 25,
50, 100, 200 μg/ml. The microplates were incubated at 37◦C
for 24 h under aerobic or anaerobic conditions according to
the bacterial growth requirements. T. denticola was cultured
under anaerobic conditions in TYVGS media up to 6 days
to determine the MIC. The determined MIC was the lowest
concentration of nisin that inhibited the visible growth of bacteria
compared to the zero time point, indicated by an increase (≤0.05)
in optical density (OD600). For determination of MBC, 10 μl
of these bacterial samples were removed from wells that had
bacterial concentrations equivalent to and higher than the MIC,
and inoculated on appropriate agar plates or in TYGVS broth
medium. The MBC was deﬁned as the lowest concentration of
nisin that killed at least 99.9% of the bacteria in a given time.
Human Saliva Collection and Preparation:
Multi-Species Inoculum and Nutrient Source
A saliva collection protocol was reviewed and given
“not regulated status” by the University of Michigan
Institutional Review Board (IRB) for Human Subject Research
(HUM00095026). This protocol has been used previously (Nance
et al., 2013; Samarian et al., 2014). Brieﬂy, for the collection
of pooled human whole saliva, the protocol required that at
least six healthy individuals donate saliva. These individuals
had not consumed any food or beverages besides water during
the 2 h prior to donation. All donors were non-smokers and
had not been prescribed antibiotics for the preceding three
months. Collected saliva was prepared for one of two purposes:
to be used as a cell-containing saliva (CCS) inoculum or to
be used as a cell-free saliva (CFS) nutrient source for bioﬁlm
growth. CCS was prepared by mixing native, pooled saliva with
glycerol in a 75%/25% ratio, respectively, and then separated
into 3 ml aliquots for storage at −80◦C. CFS was prepared by
adding 2.5 mM dithiothreitol (DTT) to the saliva then allowing
it to stand for 10 min on ice followed by centrifugation at
17000 × g for 30 min. The resulting supernatant was mixed with
distilled water to a ﬁnal concentration of 25% and ﬁlter sterilized
through 0.2-μm syringe ﬁlter with a cellulose polyethersulfone
membrane (VWR, Radnor, PA, USA). Aliquots of 30 ml were
stored at −80◦C.
Effect of Nisin on Biofilm Development in a
Static Model System
Twenty-four well glass bottom sensoplates (Greiner Bio-One,
Monroe, NC, USA) were used for the static model system
(Kolderman et al., 2015). Fifteen microliter of CCS was
inoculated into each well with 1.5 ml of CFS with or without nisin
(0.5–50 μg/ml). Upon inoculation, the bioﬁlms were incubated
for 20–22 h at 37◦C for overnight growth. Following overnight
incubation, the CFS that remained in each well was aspirated.
All wells were then washed with 500 μl of phosphate buﬀered
saline solution (PBS) three times. Following the wash, PBS
in each well was aspirated, and bioﬁlms were stained using
formulated BacLight LIVE/DEAD bacterial viability staining
solution (Invitrogen, Carlsbad, CA, USA) or Syto-9 nucleic acid
stain (Invitrogen, Carlsbad, CA, USA) prepared according to the
manufacturer’s instructions. Syto-9 stain was used to quantify
the total DNA content of the bioﬁlm. Two hundred and ﬁfty
microliter of LIVE/DEAD or 250 μl of Syto-9 solutions were
added to each well and incubated for 45min at room temperature
and washed with 500 μl of PBS three times. For capturing three-
dimensional (3D) images of bioﬁlms, confocal laser scanning
microscopy was used as described below. The total DNA content
of the bioﬁlm was measured using a Victor X3 2030 Multi-
label reader (PerkinElmer, Waltham, MA, USA) by detecting
ﬂuorescence intensity at 530 nm.
Effect of Nisin on Biofilm Development in a
Controlled Flow Microfluidic System
Forty-eight-well Bioﬂux microﬂuidic plates (Fluxion, San
Francisco, CA, USA) in conjunction with the Bioﬂux 200
system (Fluxion, San Francisco, CA, USA) were used for the
microﬂuidic model system (Nance et al., 2013; Samarian et al.,
2014). Prior to adding the CCS, the microﬂuidic channels were
ﬁrst pre-treated with CFS for cell attachment, salivary pellicle
formation, and bioﬁlm development. One hundred microliter
of CFS was added to each outlet well, then ﬂowed toward the
inlet well at 1.0 dyn/cm2 (equivalent to the ﬂow rate of 93 μl/h,
corresponding to a shear of 100 s−1 through the channel) for
2 min at room temperature. Flow was then stopped and the
plate was incubated at room temperature for 20 min. Once
Frontiers in Microbiology | www.frontiersin.org 3 June 2015 | Volume 6 | Article 617
Shin et al. Nisin inhibits multi-species oral biofilms
pre-treatment incubation was completed, the CFS remaining
in each outlet well was transferred to the corresponding inlet
well, then 100 μl of CCS was added to each outlet well. To
introduce bacterial cells into the plate channel for viewing
bioﬁlm growth, the CCS was ﬂowed from outlet to inlet wells at
1.0 dyn/cm2 for 6 s at 37◦C. Upon inoculation of bacterial cells
into the growth/viewing channels, cell seeding was conﬁrmed
visually with a Nikon Eclipse TCS-100 inverted light microscope
equipped with a 20X0.40 NA PH1 inﬁnity-corrected objective.
The plate was then set to incubate at 37◦C for 40 min to allow cell
adherence and initial growth of the bioﬁlm prior to the nutrient
ﬂow. Following incubation, CCS was aspirated from each outlet
well and 800 μl of CFS with or without nisin (0.5–50 μg/ml) was
added to each inlet well. Plates were then incubated at 37◦C for
20–22 h with controlled ﬂow of 0.2 dyn/cm2 (ﬂow rate of 19μl/h,
corresponding to a shear of 20 s−1) for overnight bioﬁlm growth.
Following overnight incubation, CFS in each inlet and outlet
well was aspirated. One hundred microliter of PBS was added
to each inlet well and ﬂowed at room temperature for 20 min at
0.2 dyn/cm2 to remove remaining treatment solution. Following
the wash, PBS in the inlet wells was aspirated, and bioﬁlms
were stained using formulated BacLight LIVE/DEAD bacterial
viability staining solution (Invitrogen, Carlsbad, CA, USA).
One-hundred microliter of formulated BacLight solution was
added to each inlet wells and ﬂowed at 0.2 dyn/cm2 for 45 min
at room temperature to allow staining of the bioﬁlms. Once the
staining was complete, the remaining solutions in the inlet wells
were aspirated and 100 μl of PBS was added to each inlet well
and ﬂowed at 0.2 dyn/cm2 for 20 min at room temperature to
remove any excess stain in the Bioﬂux channels. For capturing
3D images of bioﬁlms, confocal laser scanning microscope was
used as described below.
Disruption of Pre-Formed Biofilms by Nisin
To study the eﬀect of nisin on pre-formed bioﬁlms and to
precisely control the exposure times, bioﬁlms were inoculated
and grown in 24 well Sensoplates (Greiner Bio-One, Monroe,
NC, USA) as described above using CCS and CFS for 20–22 h at
37◦C. Following overnight growth, the bioﬁlms were treated with
nisin (10, 50 μg/ml) with short exposure times (1, 5, 10 min).
Following the treatment of pre-formed bioﬁlms with or without
nisin in CFS, all wells were washed with PBS three times. The
same bioﬁlm staining protocol was followed as described above.
Confocal Laser Scanning Microscopy and
Quantitative Analysis of Biofilms
After nisin treatment, bioﬁlms were imaged using Leica confocal
laser scanning microscopy (CLSM, SPE, Leica, IL, USA) with a
40X1.25 NA HCX PL APO inﬁnity-corrected oil or a HCX PL
APO 40X/0.85 CORR CS objective. All bioﬁlms were stained
with the BacLight Live/Dead Bacterial Viability kit (Invitrogen,
Carlsbad, MA, USA), which contains the nucleic acid stains
Syto-9 (green signal) and propidium iodide (red signal) as
described above. Once the microscopy images were taken,
bioﬁlms were rendered as 3D structures with Imaris (Bitplane,
Zurich, Switzerland) computer imaging software. Image stacks
were treated equally and the signal intensity of rendered 3D
bioﬁlm structures were conﬁrmed using histograms generated in
Imaris. Imaris allowed for the visualization of bioﬁlm architecture
in three dimensions, penetration of nisin into bioﬁlms (inferred
by the extent and degree of the red signal), and the preparation
of 3D ﬁles for the quantiﬁcation of bioﬁlm structure using
the computer software program Comstat2. For detailed bioﬁlm
analysis, Comstat2 was used to determine the bioﬁlm biovolume
(total amount of space/biomass occupied by a bioﬁlm), average
thickness (thickness of each bioﬁlm extending from the bottom to
the top of the growth/viewing channel surface), and roughness (a
measure of heterogeneity in bioﬁlm architecture). The degree of
killing, based on green (Syto-9; live) and red (PI; dead/damaged)
pixel intensity for every pixel in all 3D planes were evaluated
using ImageJ (National Institutes of Health). The percentages of
live to dead/damaged cells was determined by ﬁrst multiplying
the total number of pixels by the level of intensity (0–255) and
then summing the total value for both the LIVE and DEAD
signals from each image stack recorded. All renderings and
quantiﬁcation analyses were performed on a dedicated laptop
computer equipped with an Intel Core i5 CPU with 8 GB RAM,
64-bit operating system (MSI Computer Corp., Industry, CA,
USA).
Cell Culture
A direct cell outgrowth technique was used to obtain primary
periodontal ligament (PDL) cells and gingival ﬁbroblast (GF)
cells as previously described (Scanlon et al., 2011). These
cells were maintained in minimum essential medium alpha
(α-MEM) supplemented with 10% fetal bovine serum (FBS),
1% penicillin/streptomycin, and 1% fungizone (Gibco, Life
Technologies, Grand Island, NY, USA). Passage 3 or 4 PDL
and GF cells were used for experiments. Primary human
oral keratinocytes (OK) were purchased from Science Cell
Research Laboratories (Carlsbad, CA, USA) and maintained in
keratinocyte growth medium (KGM) supplemented with OK
growth supplements (OKGS) and 1% penicillin/streptomycin.
Passage 1 or 2 OK cells were used for experiments. Osteoblast-
like cells were purchased from American Type Culture Collection
(MG63; Manassas, VA, USA) and maintained in α-MEM
supplemented with 10% FBS, 1% penicillin/streptomycin, and 1%
fungizone. Passage 2 to 4 MG63 cells were used for experiments.
Apoptosis Staining and Microscopy
To assess the eﬀects of nisin on cell viability and nuclear
morphology, an acridine orange/ethidium bromide (AO/EB)
staining assay was used as described previously (Ribble et al.,
2005; Kasibhatla et al., 2006). AO (Acros Organics, Geel,
Belgium) and EB (Bio-Rad laboratories, Berkeley, CA, USA) are
ﬂuorescent DNA binding dyes that can be combined to assess
apoptotic cellular changes and cell membrane integrity. Using
a 96-well microplate (Thermo Scientiﬁc, Waltham, MA, USA),
cells (GF, PDL, OK, and MG63 cells) were plated at 2 × 104
cells/cm2 and allowed to adhere and spread overnight. After 24 h,
cell cultures were exposed to nisin (ﬁnal concentrations: 1, 10,
100, 200, 400, 800 μg/ml) or left untreated and incubated for a
following 24–48 h at 37◦C. Following each treatment period, the
cells were stained with the AO/EB dye solution for one minute
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under gentle agitation. The AO/EB dye reagent was comprised
of 100 μg/ml of ethidium bromide and 100 μg/ml of acridine
orange in PBS. The dye solution was removed and the cells were
viewed and imaged using an epiﬂuorescence microscope (Eclipse
50i, Nikon, Melville, NY, USA). For cell counting, each well
was divided into two halves where a minimum of 150 cells was
counted per half at 4× magniﬁcation. Cell viability, apoptosis,
and necrosis were assessed as described previously (Ribble et al.,
2005; Kasibhatla et al., 2006). Experiments were performed in
triplicate.
Cell Proliferation Assay
The eﬀect of nisin on cell proliferation was assessed by measuring
the level of intracellular lactate dehydrogenase (LDH) activity
using the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) per
manufacturer’s recommendations. Using a 96-well microplate
(Thermo Scientiﬁc, Waltham,MA, USA), the cells (GF, PDL, OK,
and MG63 cells) were plated at 2 × 104 cells/cm2 and allowed to
adhere and spread overnight. The subsequent day, the cells were
treated with diﬀerent concentrations of nisin (10–800 μg/ml) for
24–48 h. After 24 or 48 h, 10 μl of the CCK-8 solution was added
to each well and incubated at 37◦C for 3 h, then absorbance
was measured at 450 nm using a microplate reader (Spectra Max
M2, Molecular Devices, Sunnyvale, CA, USA) to determine the
LDH activity. Cell proliferation was evaluated based on the LDH
activity measured as absorbance values at 450 nm.
Statistical Analysis
Values are expressed as mean values ± SD. Independent t-tests
were used to compare the control (nisin-free) with nisin-treated
samples. The diﬀerence between the viability, apoptosis, and
necrosis was analyzed by ANOVA, using Dunnett’s method.
Individual P-values for each data set are indicated either
individually or as a group in each ﬁgure. All experiments were
repeated at least three times. Values of P < 0.05 were considered
signiﬁcant, and P < 0.01 were considered highly signiﬁcant.
Results
Antimicrobial Activity of Nisin on Oral Biofilm
Colonizers
TheMICs andMBCs of nisin on oral bacterial species are listed in
Table 1. The MIC and MBC of nisin ranged from 2.5 to 50 μg/ml
and 15 to 200 μg/ml, respectively, for early, middle, and later
colonizers of dental plaque (Table 1). S. mutans, a cariogenic
Gram-positive bacteria, showed a 1.5- to 3-fold higher sensitivity
to nisin when compared to the two commensal organisms
S. gordonii and S. oralis (Figure 1; Table 1). F. nucleatum,
a Gram-negative bacteria known for its prominent role in
coaggregation with both early and later colonizers of dental
plaque showed the least susceptibility amongst the tested species
with a MIC of 50 μg/ml (Figure 1; Table 1). In addition, nisin
exerted antimicrobial activities against the known Gram-negative
periodontal pathogens, including P. gingivalis, P. intermedia, A.
actinomycetemcomitans, and T. denticola (Figure 1; Table 1)
at nisin concentrations between 2.5 and 20 μg/ml. Amongst
TABLE 1 | Minimum inhibitory concentrations (MICs) and minimum
bactericidal concentrations (MBCs) of planktonic oral pathogens.
Oral microorganisms MIC MBC MBC/MIC
Gram positive – Early, middle colonizers of oral biofilm
Streptococcus gordonii DL1 40 μg/ml 150 μg/ml 3.75
S. oralis SO34 30 μg/ml 150 μg/ml 5
S. mutans UA159 20 μg/ml 100 μg/ml 5
Actinomyces odontolyticus ATCC
17982
10 μg/ml 30 μg/ml 3
S. mutans ATCC 25175 10 μg/ml 200 μg/ml 20
Gram negative – Late colonizers of oral biofilm
Fusobacterium nucleatum ATCC
25586
50 μg/ml 150 μg/ml 3
Aggregatibacter
actinomycetemcomitans Y4
15 μg/ml 100 μg/ml 6.67
Porphyromonas gingivalis W83 20 μg/ml 100 μg/ml 5
Porphyromonas gingivalis ATCC
33277
15 μg/ml 100 μg/ml 6.67
Prevotella intermedia clinical
isolate
10 μg/ml 150 μg/ml 15
Treponema denticola ATCC
35405
2.5 μg/ml 15 μg/ml 6
MBC/MIC ratio of >4 indicates that nisin has a bacteriostatic effect. MBC/MIC ratio
of <4 indicates that nisin has a bactericidal effect (Pankey and Sabath, 2004).
the later colonizers of oral bioﬁlms, T. denticola exhibited the
highest sensitivity to nisin with a MIC of 2.5 μg/ml and MBC
of 15 μg/ml.
The Anti-biofilm Effects of Nisin on Formation
of Multi-Species Biofilms
Saliva derived multi-species bioﬁlms were grown with or without
nisin using static and microﬂuidic model systems. Under the
static growth condition, early signs of bioﬁlm membrane damage
was observed at nisin concentrations ≥0.5 μg/ml (Figure 2A).
From confocal microscopy imaging and quantitative analysis, the
bioﬁlm growth was signiﬁcantly reduced at nisin concentrations
≥4 μg/ml (Figure 2C). In the static system, the average
bioﬁlm biomass and thickness of the control bioﬁlms were
27.25 μm3/μm2 and 29.33 μm (Figure 2B). The average bioﬁlm
biomass and thickness of the nisin treated bioﬁlms at 4 μg/ml
were 3.26 μm3/μm2 and 3.05 μm (Figure 2B). At 8 μg/ml
nisin, the bioﬁlm growth and architecture was abrogated when
compared to the control conditions (Figure 2A).
Under controlled ﬂow microﬂuidic growth conditions, the
anti-bioﬁlm eﬀects of nisin were exerted at concentrations
≥0.5 μg/ml (Figure 3A). The average bioﬁlm biomass and
thickness of the control bioﬁlms were 30.88 μm3/μm2 and
31.02μm(Figure 3B). The average bioﬁlm biomass and thickness
of the nisin treated bioﬁlms at 1 μg/ml were 5.06 μm3/μm2 and
7.17 μm (Figure 3B). The formation of bioﬁlms was absent at
4 μg/ml (Figures 3A,B).
When evaluated under both bioﬁlm model systems, bioﬁlm
biomass and thickness were signiﬁcantly reduced when the
bioﬁlms were grown in presence of nisin at concentrations
≥1 μg/ml (Figures 2B and 3B). The roughness coeﬃcient values
of the bioﬁlms increased in a dose-dependent manner, suggesting
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FIGURE 1 | Nisin inhibits the growth of cariogenic and periodontal
pathogens. Using a broth dilution method, S. gordonii DL1, S. oralis SO34,
S. mutans UA159, A. odontolyticus ATCC 17982, S. mutans ATCC 25175, F.
nucleatum ATCC 25586, A. actinomycetemcomitans Y4, P. gingivalis W83,
P. gingivalis ATCC 33277, P. intermedia clinical isolate and T. denticola ATCC
35405 was cultured with or without nisin (0.1–200 μg/ml) on a microplate for
24 h at 37◦C, under aerobic or anaerobic conditions. The determined MIC
was the lowest concentration of nisin that inhibited the visible growth (≤0.05
increase in OD600 after 24 h growth) of the inoculated bacteria. ∗P < 0.05:
significant differences from the control (nisin-free).
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FIGURE 2 | Nisin inhibits the formation of multi-species biofilms in a
static model system. Cell-containing saliva (CCS) was inoculated in filter
sterilized cell-free saliva (CFS) for 20–22 h at 37◦C with or without nisin.
(A) Confocal microscopy images are represented in the x–y plane. A green
signal indicates viable live cells (Syto 9), a red signal indicates damaged/dead
cells (propidium iodide), (B) Biofilm biomass, thickness, and roughness [mean
(SD)] were derived from imaging of at least three separate wells (experiments),
(C) DNA content of the biofilms was quantified by absorption spectroscopy at
fluorescence intensity of 530 nm. ∗P < 0.05 and ∗∗P < 0.01: significant
differences from the control (nisin-free).
an increase in heterogeneity within the bioﬁlm architecture due
to membrane associated structural damages. Collectively, our
data suggest that nisin concentrations >8 μg/ml can inhibit the
formation of saliva derived multi-species bioﬁlms.
The Anti-biofilm Effects of Nisin on Preformed
Multi-Species Biofilms
Saliva derived multi-species bioﬁlms formed overnight (20–
22 h) under static conditions, then treated with two diﬀerent
concentrations of nisin (10, 50 μg/ml). The bioﬁlms were
treated with nisin for short exposure times (1, 5, and 10 min).
At both concentrations and at all three exposure times,
the 3D rendered confocal microscopy images of bioﬁlms
demonstrated structural damage and dissociation within the
bioﬁlm architecture (Figure 4A). When compared to the control
bioﬁlms treated with PBS, nisin treated bioﬁlms exhibited
reduced bioﬁlm biomass and thickness (Figure 4B). This
reduction in the biomass and thickness of the bioﬁlms occurred
in a dose- and time-dependent manner. At a nisin concentration
of 10 μg/ml, the viability of the bioﬁlms was only slightly
reduced for all exposure times (although statistically signiﬁcant).
However, at 50 μg/ml, much higher bioﬁlm killing was observed
at 5 and 10 min exposure times, as indicated by the confocal
microscopy imaging and Live/Dead signal quantiﬁcation of the
bioﬁlms (Figures 4A,C). In addition, the roughness coeﬃcient
values of the nisin treated bioﬁlms were signiﬁcantly increased
compared to the control bioﬁlms treated with PBS. The increase
in the roughness coeﬃcient values occurred in a time-dependent
manner at 50 μg/ml, but it did not follow a speciﬁc time-
dependent trend with 10 μg/ml.
The Effects of Nisin on Viability of Human Cells
Relevant to the Oral Cavity
The eﬀect of nisin on cell viability was assessed in human cells
that are relevant to the oral cavity. After a 24 h treatment, GF,
PDL,OK, andMG63 cells were highly tolerant to nisin treatments
(Figure 5B). With nisin treatments of up to 400 μg/ml, GF, PDL,
OK, and MG63 cells exhibited normal cell viability levels (>95%)
and cell phenotypes with minimal apoptotic characteristics. After
a 48 h treatment, GF, PDL, and OK cells exhibited normal
cell viability with nisin up to 200 μg/ml. Osteoblast-like MG63
cells exhibited the highest tolerance against nisin (Figure 5B).
At antimicrobial and anti-bioﬁlm concentrations (<100 μg/ml),
nisin treated cells maintained a normal cell shape and nuclear
phenotype compared to the untreated control cells. Only at
concentrations ≥200 μg/ml and after 48 h, cells started showing
low levels of apoptosis with chromatin condensation and nuclear
fragmentation (Figure 5A).
The Effects of Nisin on Cell Proliferation
The eﬀect of nisin on cell proliferation was assessed by measuring
the innate LDH activity of the cells (GF, PDL, OK, MG63). After
24 h with treatment of up to 800 μg/ml of nisin, GF, PDL
and MG63 cells exhibited normal cell proliferation compared
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FIGURE 3 | Nisin inhibits the formation of multi-species biofilms in a
Bioflux controlled flow microfluidic model system. CCS was added, then
fed filter sterilized CFS for 20–22 h at 37◦C with or without nisin. (A) Confocal
microscopy images are represented in the x–y plane. A green signal indicates
viable live cells (Syto 9) and a red signal indicates damaged/dead cells
(propidium iodide). (B) Biofilm biomass, thickness, and roughness [mean (SD)]
were derived from imaging of at least three separate channels (experiments).
∗P < 0.05 and ∗∗P < 0.01: significant differences from the control (nisin-free).
to the control (Figure 6). In control experiments, nisin (10–
800μg/ml) incubated inmedia alone exhibited negligible levels of
LDH activity (data no shown). Only OK cells exhibited reduced
cell proliferation after a 24 h nisin treatment at concentrations
>400 μg/ml. In addition, GF and PDL exhibited normal cell
proliferation with nisin concentrations up to 800 μg/ml, and
OK and MG63 exhibited normal cell proliferation with nisin
concentrations up to 400 μg/ml (Figure 6). At 800 μg/ml, OK
cells were unable to attach to the cell surface and proliferate. At
antimicrobial and anti-bioﬁlm concentrations (<100 μg/ml), all
cells exhibited normal cell attachment and proliferation.
Discussion
The data presented here demonstrate the potential for nisin as
an antimicrobial and anti-bioﬁlm agent against oral pathogens.
The peptide structure of nisin is characterized by the presence of
ﬁve intra-molecular rings formed by the thioether amino acids
lanthionine and 3-methyllanthionine (Wiedemann et al., 2001).
Due to its unique chemical features, it has been hypothesized
that nisin has various modes of antimicrobial action (Peschel and
Sahl, 2006) and exerts multiple antimicrobial activities based on
the interaction with multiple cellular targets (Bierbaum and Sahl,
1985; Chan et al., 1996; Pag and Sahl, 2002). However, when
used in a clinical setting, there is potential risk of developing
nisin resistance. There have been a few examples of lantibiotic
resistance noted in laboratory settings, where certain bacteria
have been reported to possess innate anti-lantibiotic mechanisms.
For example, nisinase is a dehydropeptide reductase that can
inactivate nisin (de Freire Bastos et al., 2014; Draper et al.,
2015). Nisinase activity has been associated with Lactobacillus
plantarum (Kooy, 1952), Streptococcus thermophilus (Alifax and
Chevalier, 1962), Clostridium botulinum (Rayman et al., 1983),
Lactococcus lactis sub-species cremoris, Enterococcus faecalis, and
Staphylococcus aureus (Carlson and Bauer, 1957). Thus, future
characterization of speciﬁc genetic or protein components that
may contribute to nisin resistance is needed to understand any
potential resistance issues in a clinical setting.
Previously, studies have implicated that nisin has broad-
spectrum activity against Gram-positive bacteria with limited
potency on Gram-negative bacteria (Delves-Broughton et al.,
1996; Severina et al., 1998; Cleveland et al., 2001). Our ﬁndings
demonstrate that the high purity form of nisin Z (nisin ZP,>95%
purity) exhibits antimicrobial activity against both Gram-positive
and Gram-negative oral bacteria. In comparison to recent studies
that used a low content nisin (Tong et al., 2010; Corbin et al.,
2011), our data suggests that nisin ZP (>95% purity) is much
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FIGURE 4 | Nisin disrupts the maintenance of three-dimensional
architecture of pre-formed biofilms. CCS was inoculated in filter sterilized
CFS for 20–22 h at 37◦C and treated with phosphate buffered saline solution
(PBS) solution (control) or nisin at different concentrations and incubation times.
(A) Confocal microscopy images are represented in the x–y and x–y–z plane.
A green signal indicates viable live cells (Syto 9) and a red signal indicates
damaged/dead cells (propidium iodide). (B) Biofilm biomass, thickness, and
roughness [mean (SD)] were derived from imaging of at least three separate
wells (experiments). (C) An average percentage signal from the biofilms was
determined by the Live/viable signal (green) and the Dead/damaged signal (red)
in relation to the total signal captured for both. ∗P < 0.05 and ∗∗P < 0.01:
significant differences from the control (nisin-free).
more potent than low content nisin A (2.5% purity) in inhibiting
cariogenic oral bacteria and oral bioﬁlms. These earlier studies
utilized low purity nisin, which is generally less soluble than the
high purity form. In addition, when considering the preparation
of nisin solutions, nisin A (2.5% purity) requires approximately
pH 2 whereas nisin ZP can be prepared at more neutral pH
conditions (Pag and Sahl, 2002). Nisin ZP can be easily prepared
in water at pH 7 as a colorless, odorless, and tasteless solution.
Hence, the utilization of high purity nisin ZP as a potential oral
anti-microbial rinse has promising features.
Commensal oral bacteria, such as S. gordonii and S. oralis,
exhibited lower sensitivity to nisin than the pathogenic species
S. mutans (Table 1). From the single species experiments,
the most interesting data resulted from the Gram-negative
anaerobes. Periodontal disease is strongly associated with
pathogenic bacteria such as P. gingivalis, P. intermedia, A.
actinomycetemcomitans, and T. denticola. These anaerobic
pathogens are believed to gain access to the periodontal tissues
and thereby mediate tissue damage by a complex array of host–
pathogen interactions, including modulation of inﬂammatory
host response mechanisms (Haﬀajee and Socransky, 1994;
Pihlstrom et al., 2005; Darveau, 2009). In our study, nisin at
low concentrations <20 μg/ml inhibited the growth of these
periodontal pathogens (Table 1). Amongst these pathogens,
T. denticola was highly susceptible to nisin treatment, requiring
only 2.5 μg/ml to inhibit its growth up to 6 days (Figure 1).
T. denticola comprises up to 30% of the microbiota in
diseased gingival pockets and is associated with tissue and bone
destructive mechanisms in periodontitis (Baehni et al., 1992;
Riviere et al., 1992; Gopalsami et al., 1993; Choi et al., 2003).
Thus, our ﬁndings suggest that nisin can inhibit the growth of
both Gram-positive and Gram-negative disease-associated oral
bacteria.
Dental plaque is a complex of multi-species bioﬁlm
community (Marsh, 2010). Collectively, the contained species
can withstand the constantly changing conditions of the
oral cavity and can be highly resistant to the treatment of
antimicrobial agents (Jakubovics and Kolenbrander, 2010). Since
these bioﬁlms can rapidly form and mature to develop additional
pathogenic traits, anti-bioﬁlm agents that inhibit the formation
of and disperse established bioﬁlms would beneﬁt the prevention
and treatment of oral diseases (Marsh, 2010). Using biologically
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FIGURE 5 | Nisin has minimal cytotoxicity to human cells relevant to
the oral cavity. Primary human gingival fibroblast (GF) cells, periodontal
ligament (PDL) cells, oral keratinocyte (OK) cells, and osteoblast-like cells
were incubated with nisin (1–800 μg/ml) for 24–48 h on a 96-well microplate
at 37◦C. Cells were then stained with acridine-orange/ethidium-bromide
(AO/EB) to evaluate cell viability, apoptosis and necrosis using
epifluorescence microscopy. (A) Images of the cells after 48 h incubation
period with nisin at different concentrations. (B) The cytotoxicity of nisin was
quantified by counting viable, apoptotic and necrotic cells and expressed as
bar graphs with heights representing mean % and error bars representing
SD. AO (green) stained cells with intact membrane integrity. Early apoptotic
cells stained green but contained bright green dots in the nuclei due to
chromatin condensation and nuclear fragmentation. Late apoptotic cells
stained with EB (orange) with apoptotic phenotypes. Necrotic cells stained
orange but the nuclear morphology resembled the viable cells with absence
of chromatin condensations. Mean values were calculated with SD. ∗,#,$
represent P < 0.05: significant differences from the control (nisin free) for
viability, apoptosis and necrosis, respectively.
relevant human saliva as the multi-species bioﬁlm inoculum and
growth media, our results demonstrated that nisin exerted anti-
bioﬁlm properties. Overnight incubation of nisin within saliva
caused substantial inhibition of bioﬁlm formation. Speciﬁcally,
nisin concentrations ≥0.5 and 1 μg/ml caused a signiﬁcant
reduction in bioﬁlm biomass and thickness of bioﬁlms developed
in static and microﬂuidic systems, respectively (Figures 2B
and 3B). The resulting bioﬁlms were highly disintegrated and
lacked coaggregative behavior expressed in the control untreated
bioﬁlms (Figures 2A and 3A).
Similar to preventing bioﬁlm development, the anti-bioﬁlm
properties of nisin against pre-formed bioﬁlms occurred
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FIGURE 6 | Nisin does not effect cell proliferation of human cells. The
effect of nisin on cell proliferation was assessed using a Cell Counting Kit-8
measuring the lactate dehydrogenase (LDH) activities in cells. Using a 96-well
microplate, GFs, PDL cells, OKs, and osteoblast-like cells were plated at
2 × 104 cells/cm2 and incubated for 24–48 h in the presence or absence of
nisin (1–800 μg/ml). At 24 and 48 h time points, LDH levels were measured
using absorption spectroscopy at 450 nm. Mean values were calculated with
SD. ∗P < 0.05: significant differences from the control (nisin-free).
in a dose- and time-dependent manner. As inferred by
observed changes in bioﬁlm architecture, bioﬁlms seemingly
dispersed and sloughed into smaller aggregates after a 1 min
exposure to 10 and 50 μg/ml of nisin. (Figure 4A). At
50 μg/ml and after a 5 min exposure, bioﬁlms exhibited cell
death, and membrane damage indicated by the Live/Dead
signal quantiﬁcation (Figure 4C). However, at 10 μg/ml,
signiﬁcant bacterial killing was not observed regardless
of the treatment time. The antimicrobial action of nisin
may be either bacteriostatic or bactericidal depending on
multiple factors, such as nisin concentration, bacterial
concentration, physiological state of the bacteria, and the
prevailing conditions (Delves-Broughton et al., 1996). Thus,
our data support the premise that nisin acts as a fast-acting
anti-bioﬁlm agent with both bioﬁlm-static and bioﬁlm-killing
properties.
Coaggregation of diﬀerent bacterial species is considered
critical to maintaining the stability of the architecture and
species composition of dental plaque (Hojo et al., 2009;
Katharios-Lanwermeyer et al., 2014). Coaggregation interactions
promote the development of multi-species bioﬁlms by enabling
bacterial communication and colonization of initial, middle, and
later colonizers (Kolenbrander et al., 2010). Previously, Smith
et al. (1991) demonstrated that cationic antimicrobials, such
as chlorhexidine digluconate and cetylpyridinium chloride, can
selectively inhibit coaggregation interactions of later colonizers
of dental plaque. As a cationic and a membrane acting
bacteriocin, the modes of action of nisin may be to disrupt the
coaggregation process needed to form a stable bioﬁlm. Present
data are suggestive that the likely role of nisin in inhibiting
coaggregation may be at least in part responsible for its anti-
bioﬁlm eﬀects. Assuming that the coaggregation process is
critical for developing and maintaining the bioﬁlm complex,
studies are in progress to determine the ability of nisin to
inhibit speciﬁc coaggregation interactions between oral bioﬁlm
colonizers.
After more than thirty years of use as an antiplaque agent in
the dental profession, chlorhexidine is still considered the gold
standard (Jones, 1997; Baehni and Takeuchi, 2003). However,
frequent or long-term use of chlorhexidine, although still
employed clinically, is associated with negative eﬀects (Flötra
et al., 1971; Gagari and Kabani, 1995). Previously it was
reported that direct exposure to as little as 0.0025 to 0.01%
of chlorhexidine can signiﬁcantly aﬀect cell morphology and
cell attachment of cultured GFs (Cline and Layman, 1992). In
addition, chlorhexidine is highly cytotoxic to neutrophils, human
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epithelial cells, PDL cells, ﬁbroblasts and HeLa cells
(Goldschmidt et al., 1977; Chang et al., 2001). Our study
demonstrates that orally relevant human cells are highly tolerant
to direct contact by nisin. Our data indicate that nisin at
antimicrobial and anti-bioﬁlm concentrations (<100 μg/ml) is
not cytotoxic to these cells (OKs, GFs, PDL cells, and osteoblast-
like cells) that play an integral role in the maintenance of
healthy gingival tissues. It is essential to preserve the cellular
characteristics of primary OKs, since these cells act as the
ﬁrst line of defense against the oral pathogens (Weinberg
et al., 1998; Hans and Madaan Hans, 2014). When cells were
incubated with nisin for 24–48 h, cell apoptosis was nearly
absent unless treated with nisin at >200 μg/ml, which is
more than 10-fold greater than the minimum concentration
displaying anti-bioﬁlm eﬀects. In addition, all cell types
exhibited normal cell attachment and proliferation when
treated with up to 400 μg/ml of nisin after a 24 h incubation.
Cationic antimicrobial peptides are unique in that they are
hypothesized to play an important role in the immune system
or to exert diﬀerent eﬀects on eukaryotic cells (Hancock
and Diamond, 2000). Although bacterially secreted, nisin is
known to trigger immune responses in host eukaryotic cells
(Hancock and Diamond, 2000; Begde et al., 2011). As an
immunogenic agent, nisin was reported to elevate the T-cell
population (CD4 and CD8) while reducing the B-cell population
(Pablo et al., 1999). In addition, nisin has been shown to
modulate the innate immune response through the induction
of chemokine synthesis and suppression of lipopolysaccharide
induced pro-inﬂammatory cytokines, both in vitro and in
vivo (Kindrachuk et al., 2013). Thus, at certain non-toxic
concentrations to the oral cells, nisin could potentially aid in
the induction of innate defense mechanisms to help clear the oral
pathogens.
The work presented here demonstrates that nisin is a
promising candidate for development as an oral therapeutic anti-
bioﬁlm agent. High purity food grade nisin (>95%) exerted
anti-bioﬁlm eﬀects against saliva derived multi-species bioﬁlms
without causing cytotoxic eﬀects to the human oral cells. In
addition to its long history and utilization as a food preservative,
nisin possesses great potential for other applications involving
treating clinical bacterial infections and inhibiting bioﬁlm
growth. Further investigation of the clinical role of nisin in
modulating the microbiome of the bioﬁlm community and its
immunomodulatory role in human oral cells are necessary to
determine its potential as a therapeutic or prophylactic agent
against oral diseases.
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